Literature DB >> 12802519

Lymphocyte subsets and T(h)1/T(h)2 immune responses in patients with adenocarcinoma of the oesophagus or oesophagogastric junction: relation to pTNM stage and clinical outcome.

Johanna W van Sandick1, Marja A Boermeester, Suzanne S Gisbertz, Ineke J M ten Berge, Theo A Out, Tineke C T M van der Pouw Kraan, J Jan B van Lanschot.   

Abstract

INTRODUCTION: Recent studies have indicated that the cytokines produced by CD4(+) T helper type 1 (T(h)1) and type 2 (T(h)2) cells are critically important in antitumour immunity and perhaps clinical outcome. From this perspective, we investigated the immunocompetence of patients with previously untreated cancer of the oesophagus or oesophagogastric junction (OGJ) in relation to stage of disease and postoperative survival.
METHODS: Blood samples were taken prior to surgery from 32 patients with adenocarcinoma of the oesophagus or OGJ. Ten healthy volunteers served as normal controls. T-cell and monocyte subpopulations were determined using flow cytometry. Monocyte as well as T(h)1- and T(h)2-lymphocyte cytokine levels were assessed in stimulated whole blood cultures.
RESULTS: Absolute T-cell and monocyte (subset) counts as well as monocyte cytokine levels were similar among patients and controls. Production of T(h)1-type cytokines was higher in patients than in controls (IFN-gamma, p=0.01; IL-2, p=0.05), whereas T(h)2-type cytokine levels were comparable (IL-4, p=0.5; IL-13, p=0.3). T-cell CD4(+)/CD8(+) ratios decreased as pTNM stage worsened (stage I/II vs stage III/IV, p=0.009). Of all measured immunological parameters, only IL-2 production significantly affected both overall survival ( p=0.015) and disease-free survival ( p=0.0062). High IL-2 levels corresponded with a favourable prognosis.
CONCLUSIONS: Patients awaiting surgery for adenocarcinoma of the oesophagus or oesophagogastric junction demonstrated a shift in the T(h)1/T(h)2 balance-in favour of T(h)1-compared with healthy volunteers. The ability of T cells to produce IL-2 was related to survival indicating a crucial role of T(h)1-type cells in antitumour immunosurveillance.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12802519     DOI: 10.1007/s00262-003-0406-7

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  10 in total

1.  Morphine, but not ketamine, decreases the ratio of Th1/Th2 in CD4-positive cells through T-bet and GATA3.

Authors:  Mei Gao; Jie Sun; Wenjie Jin; Yanning Qian
Journal:  Inflammation       Date:  2012-06       Impact factor: 4.092

Review 2.  [Relaparotomy in secondary peritonitis Planned relaparotomy or relaparotomy on demand?].

Authors:  B Lamme; C W Mahler; J W O van Till; O van Ruler; D J Gouma; M A Boermeester
Journal:  Chirurg       Date:  2005-09       Impact factor: 0.955

3.  Combined influence of adjuvant therapy and interval after surgery on peripheral CD4(+) T lymphocytes in patients with esophageal squamous cell carcinoma.

Authors:  Yang Ling; Lieying Fan; Chunlei Dong; Jing Zhu; Yongping Liu; Yan Ni; Changtai Zhu; Changsong Zhang
Journal:  Exp Ther Med       Date:  2010-01-01       Impact factor: 2.447

Review 4.  Coevolution of Leukemia and Host Immune Cells in Chronic Lymphocytic Leukemia.

Authors:  Noelia Purroy; Catherine J Wu
Journal:  Cold Spring Harb Perspect Med       Date:  2017-04-03       Impact factor: 6.915

Review 5.  The immune contexture in human tumours: impact on clinical outcome.

Authors:  Wolf Herman Fridman; Franck Pagès; Catherine Sautès-Fridman; Jérôme Galon
Journal:  Nat Rev Cancer       Date:  2012-03-15       Impact factor: 60.716

6.  FLOT and CROSS chemotherapy regimens alter the frequency of CD27+ and CD69+ T cells in oesophagogastric adenocarcinomas: implications for combination with immunotherapy.

Authors:  Maria Davern; Noel E Donlon; Andrew S Sheppard; Klaudia D Majcher; Fiona O' Connell; Aisling B Heeran; Malika Grant; Robert A Farrell; Conall Hayes; Dara Bracken-Clarke; Melissa J Conroy; Emma Foley; Dermot O' Toole; Anshul Bhardwaj; Narayanasamy Ravi; John V Reynolds; Stephen G Maher; Jacintha O' Sullivan; Joanne Lysaght
Journal:  J Cancer Res Clin Oncol       Date:  2022-08-20       Impact factor: 4.322

Review 7.  Impact of the Tumor Microenvironment for Esophageal Tumor Development-An Opportunity for Prevention?

Authors:  Martin Borgmann; Michael Quante
Journal:  Cancers (Basel)       Date:  2022-04-30       Impact factor: 6.575

8.  Lymphangiogenesis and cancer.

Authors:  Ailsa Christiansen; Michael Detmar
Journal:  Genes Cancer       Date:  2011-12

9.  Response of lymphocyte subsets and cytokines to Shenyang prescription in Sprague-Dawley rats with tongue squamous cell carcinomas induced by 4NQO.

Authors:  Canhua Jiang; Dongxia Ye; Weiliu Qiu; Xiuli Zhang; Zhiyuan Zhang; Di He; Ping Zhang; Wantao Chen
Journal:  BMC Cancer       Date:  2007-03-05       Impact factor: 4.430

10.  Trial watch: Prognostic and predictive value of the immune infiltrate in cancer.

Authors:  Laura Senovilla; Erika Vacchelli; Jerome Galon; Sandy Adjemian; Alexander Eggermont; Wolf Hervé Fridman; Catherine Sautès-Fridman; Yuting Ma; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2012-11-01       Impact factor: 8.110

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.